Max Hodak's Science Corp. is about to take a major step forward. The company is preparing to implant its first brain sensor in a human patient, marking a significant milestone in the neurotechnology space.
Hodak, who co-founded Neuralink before starting Science Corp., is taking a different approach than his former company. Instead of focusing on brain-computer interfaces for communication, Science Corp.'s device targets therapeutic applications for neurological conditions.
The sensor works by delivering gentle electrical stimulation to damaged brain or spinal cord cells. The goal is to encourage healing in areas that have been compromised by injury or disease.
For anyone following the brain-computer interface race, this matters because it shows how diverse the applications are becoming. While companies like Neuralink focus on restoring movement and communication, Science Corp. is betting on regenerative approaches that could address a wider range of conditions.
The move to human trials is always the critical moment for any medical device company. If Science Corp.'s sensor proves successful, it could open up new treatment pathways for patients with limited options today.
This is part of a broader trend where former Neuralink executives are launching competing ventures with different technical approaches. The neurotechnology field is expanding rapidly, with multiple teams racing to prove their concepts work in real patients.
